A Phase 2 Dose-Confirmation Study of Oral ASTX727, a Combination of Oral Decitabine with a Cytidine Deaminase Inhibitor (CDAi) Cedazuridine (E7727), in Subjects with Myelodysplastic Syndromes (MDS)

被引：0
|
作者：
Garcia-Manero, Guillermo
Griffiths, Elizabeth A.
Roboz, Gail J.
Busque, Lambert
Wells, Richard A.
Odenike, Olatoyosi
Steensma, David P.
Yee, Karen W. L.
Faderl, Stefan
Amrein, Philip C.
Michaelis, Laura C.
Kantarjian, Hagop M.
Oganesian, Aram
Lowder, James N.
Azab, Mohammad
Savona, Michael R.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4274
引用
收藏
页数：4
相关论文
共 20 条
  • [1] DOSE-CONFIRMATION PK/PD STUDY OF ORAL ASTX727, A COMBINATION OF ORAL DECITABINE WITH A CYTIDINE DEAMINASE INHIBITOR (CDAI) E7727, IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Griffiths, E. A.
    Roboz, G. J.
    Bergeron, J.
    Wells, R.
    Odenike, O.
    Steensma, D.
    Yee, K. W.
    Faderl, S.
    Amrein, P.
    Michaelis, L. C.
    Kantarjian, H.
    Oganesian, A.
    Lowder, J.
    Taverna, P.
    Azab, M.
    Savona, M. R.
    HAEMATOLOGICA, 2017, 102 : 489 - 490
  • [2] PHASE 1 DOSE-ESCALATION STUDY OF ORAL ASTX727, A COMBINATION OF ORAL DECITABINE WITH A CYTIDINE DEAMINASE INHIBITOR (CDAI) E7727, IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Savona, M. R.
    Odenike, O.
    Amrein, P.
    Steensma, D.
    DeZern, A.
    Michaelis, L.
    Faderl, S.
    Oganesian, A.
    Lowder, J.
    Taverna, P.
    Azab, M.
    Garcia-Manero, G.
    HAEMATOLOGICA, 2016, 101 : 73 - 73
  • [3] Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)
    Savona, Michael R.
    Odenike, Olatoyosi
    Amrein, Philip C.
    Steensma, David P.
    Harb, Wael A.
    DeZern, Amy E.
    Michaelis, Laura C.
    Faderl, Stefan
    Lowder, James N.
    Taverna, Pietro
    Oganesian, Aram
    Dua, Richa
    Nawabi, Roya
    Azab, Mohammad
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
  • [4] Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study
    Garcia-Manero, Guillermo
    Odenike, Olatoyosi
    Amrein, Philip C.
    Steensma, David P.
    DeZern, Amy E.
    Michaelis, Laura C.
    Faderl, Stefan
    Kantarjian, Hagop M.
    Lowder, James N.
    Taverna, Pietro
    Oganesian, Aram
    Zhang, Xiaoping
    Azab, Mohammad
    Savona, Michael R.
    BLOOD, 2016, 128 (22)
  • [5] DEVELOPMENT OF A SEMI-MECHANISTIC PK/PD MODEL OF AN ORAL FIXED DOSE COMBINATION OF CDA INHIBITOR E7727 WITH DECITABINE (ASTX727) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES
    Burroughs, E. G.
    Oganesian, A.
    Zhang, X.
    Hoke, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S81 - S81
  • [6] Preclinical Data In Cynomolgus (cyn) Monkeys Of ASTX727, a Novel Oral Hypomethylating Agent (HMA) Composed Of Low-Dose Oral Decitabine Combined With a Novel Cytidine Deaminase Inhibitor (CDAi) E7727
    Oganesian, Aram
    Redkar, Sanjeev
    Taverna, Pietro
    Joshi-Hangal, Rajashree
    Azab, Mohammad
    BLOOD, 2013, 122 (21)
  • [7] ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients
    Garcia-Manero, Guillermo
    Bachiashvili, Kimo
    Amin, Harshad
    Traer, Elie
    Pollyea, Daniel A.
    Sallman, David A.
    Al-Kali, Aref
    Cripe, Larry D.
    Berdeja, Jesus G.
    Griffiths, Elizabeth A.
    Mohan, Sanjay R.
    Sano, Yuri
    Oganesian, Aram
    Keer, Harold N.
    Yacoub, Abdulraheem
    BLOOD, 2022, 140 : 1112 - 1114
  • [8] PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS
    Garcia-Manero, G.
    Bachiashvili, K.
    Amin, H.
    Traer, E.
    Pollyea, D.
    Sallman, D.
    Al-Kali, A.
    Cripe, L.
    Berdeja, J.
    Griffiths, E.
    Mohan, S.
    Vachhani, P.
    Sano, Y.
    Oganesian, A.
    Keer, H.
    Yacoub, A.
    LEUKEMIA RESEARCH, 2023, 128
  • [9] Evaluation of Potential Low-Dose Regimens of Oral Fixed-Dose Combination of Cytidine Deaminase Inhibitor E7727 with Decitabine (ASTX727-LD) to Minimize Decitabine-Mediated Neutropenia in Low-Risk MDS Subjects Using Systems Pharmacology Modeling
    Nikitich, A.
    Demin, O., Jr.
    Demin, O.
    Oganesian, A.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S14 - S15
  • [10] A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia
    Bazinet, Alexandre
    Garcia-Manero, Guillermo
    Short, Nicholas J.
    Valero, Yesid Alvarado
    Abuasab, Tareq
    Islam, Md Rabiul
    Montalbano, Kathryn
    Issa, Ghayas C.
    Maiti, Abhishek
    Yilmaz, Musa
    Jain, Nitin
    Masarova, Lucia
    Kornblau, Steven M.
    Jabbour, Elias
    Montalban-Bravo, Guillermo
    Pierce, Sherry
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Daver, Naval
    Konopleva, Marina Y.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    BLOOD, 2023, 142
12